Because inflammatory cytokines, i.e., TNF-α, IL-17, and IL-23, are involved in the pathogenesis of psoriasis, the high safety profile of DXM and its general immunomodulatory effects are advantages in its clinical application as a potential therapeutic treatment for psoriasis [27]. The gene discussed is IL17A; the disease is psoriasis.